1Willems FF,Aengevaeren WR,Boers GH,et al.Coronary endothelial function in hyperhomocyst einemia:Improvement after treatment with folicacid and cobalamin in patients with coronary artery disease[J].Jam Coll Cardiol,2002,40(4):766-772.
2Ueland PM,Hustad S,Sehneede J,et a1.Biological and clinical implieations of the MTHFR C677T polymor phism[J].Trends Pharmaeol Sei,2001,22(4):195-201.
3Tsai MY,Loria CM,Cao J,et a1.Clinical utility of genotyping the 677 C>T variant of methylenetetrahydrofolate reduetase in humans is decreased in the post-folie acid fortification era[J].J Nutr,2009,139(1):33-37.
4Frosst P,Blom HJ,Milos R,et al.A candidat e genetic risk factor for vasculardisease:a common mutation in methylenetetrahydrof olate reductase[J].Nat Genet,1995,10(1):111-112.
5Graham IM,Daly LE,Refsum HM,et al.Plasma homocysteine as a risk factor for vascular disease.The European Concerted Action Project[J].JAMA,1997,277(22):1775-1781.
6Morita H,Taguchi J,Kurihara H,et a1.Genetic polymorphism of5,10-methyletetrahydrofo-late ruductase(MTHFR)as a risk factor for coronary artery disease[J].Circulation,1997,95(8):2023-2026.
7Muniz MT,Siqueira ER,Fonseca RA,et a1.Evaluation of MTHFR C677T gene polymorphism and homocysteine level in coronary atherosclerotie disease[J].J Arq Bras Endocrinol Metabol,2006,50(6):1059-1065.
